Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of PDS0101 plus Keytruda in recurrent or metastatic HPV16-associated head and neck cancer
ISRCTN15021247Phase 2Completed
- Sponsor
- Syneos Health
- Start
- Mar 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
01
Overview
Phase 2, open-label trial of PDS0101 and pembrolizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Syneos Health. Primary endpoint: Best overall response. Started Mar 2021; status: completed.
02
Drugs
PDS0101pembrolizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ISRCTN15021247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15021247.